LongeVC Portfolio Company Unnatural Products to Be Acquired by argenx
LongeVC portfolio company Unnatural Products (UNP) has entered into a definitive agreement to be acquired by argenx for $550 million upfront, plus contingent value rights tied to development and regulatory milestones, for a total potential value of up to approximately $1.15 billion.
The deal builds on a two-year research collaboration between the companies. After closing, expected by year-end, UNP's team and macrocyclic peptide platform will continue in Santa Cruz as argenx's dedicated macrocyclic peptide discovery hub. Founded in 2016, UNP designs oral macrocyclic peptides for previously undruggable targets and has partnerships with Novartis, Merck and BridgeBio.